Incyte Corp. | Balance Sheet

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
510
601
708
809
1,170
1,438
Total Accounts Receivable
35
58
114
149
266
308
Inventories
-
-
2
4
6
7
Other Current Assets
11
40
18
33
62
79
Total Current Assets
556
699
842
994
1,505
1,832
Net Property, Plant & Equipment
27
82
86
168
260
320
Total Investments and Advances
15
14
49
33
135
100
Intangible Assets
-
-
-
426
392
371
Other Assets
32
35
30
18
10
23
Total Assets
630
830
1,007
1,639
2,303
2,646
ST Debt & Current Portion LT Debt
-
86
-
-
7
Accounts Payable
19
24
30
76
68
Other Current Liabilities
89
111
138
198
300
Total Current Liabilities
108
222
168
274
375
Long-Term Debt
662
603
620
651
17
Provision for Risks & Charges
-
-
-
281
260
Deferred Taxes
1
20
-
-
-
Other Liabilities
52
67
48
13
20
Total Liabilities
823
912
836
1,219
672
Common Equity (Total)
193
82
171
419
1,631
Total Shareholders' Equity
193
82
171
419
1,631
Total Equity
193
82
171
419
1,631
Liabilities & Shareholders' Equity
630
830
1,007
1,639
2,303

About Incyte

View Profile
Address
1801 Augustine Cut-Off
Wilmington Delaware 19803
United States
Employees -
Website http://www.incyte.com
Updated 07/08/2019
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A.